Camidanlumab tesirine - CAS 1853239-04-9

Camidanlumab tesirine (ADCT 301) is an ADC consisting of a human IgG1 antibody, HuMax-TAC, targeting CD25, which is conjugated through a dipeptide-cleavable linker to pyrrolobenzodiazepine (PBD) dimer payloads. The drug-antibody ratio (DAR) of Camidanlumab tesirine is 2.3. It binds to human CD25 with picomolar affinity and exhibits potent and selective cytotoxicity against human lymphoma cell lines expressing CD25.

Antibody-Drug Conjugates (ADCs), Interleukin

Immunology/Inflammation, Antibody-drug Conjugate/ADC Related

1853239-04-9

-20°C

Ice Packs

Inhibitory Antibodies